Literature DB >> 6796309

Carrier detection in Sanfilippo syndrome type B: report of six families.

J M Vance, P M Conneally, R S Wappner, P L Yu, I K Brandt, M A Pericak-Vance.   

Abstract

Serum samples from 175 individuals in six Sanfilippo syndrome type B (SFB) families and 360 White controls were assayed for serum alpha-N-acetyl-D-glucosaminidase (NAG) activity. Only minimal overlap was observed between the controls' NAG activity distribution and that of the 12 obligate heterozygotes. The distribution of NAG activity was log transformed to reduce skewness, and segregation of family members with a prior risk of being a SFB carrier was well within expected limits. However, in one consanguineous family the NAG activity of both parents of one SFB obligate heterozygote was within the normal range for NAG activity. Plausible explanations for this finding are discussed. Additionally, the serum NAG activity of one control and her mother were found to lie within one standard deviation of the obligate heterozygote mean. These individuals are most probably carriers for SFB.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6796309     DOI: 10.1111/j.1399-0004.1981.tb01818.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  3 in total

1.  Mucopolysaccharidosis type IIIB (Sanfilippo B): identification of 18 novel alpha-N-acetylglucosaminidase gene mutations.

Authors:  S Bunge; A Knigge; C Steglich; W J Kleijer; O P van Diggelen; M Beck; A Gal
Journal:  J Med Genet       Date:  1999-01       Impact factor: 6.318

Review 2.  Mucopolysaccharidosis type III (Sanfilippo syndrome) and misdiagnosis of idiopathic developmental delay, attention deficit/hyperactivity disorder or autism spectrum disorder.

Authors:  Frits A Wijburg; Grzegorz Węgrzyn; Barbara K Burton; Anna Tylki-Szymańska
Journal:  Acta Paediatr       Date:  2013-02-06       Impact factor: 2.299

Review 3.  Molecular Bases of Neurodegeneration and Cognitive Decline, the Major Burden of Sanfilippo Disease.

Authors:  Rachel Heon-Roberts; Annie L A Nguyen; Alexey V Pshezhetsky
Journal:  J Clin Med       Date:  2020-01-27       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.